The BTI research group is committed to dermatology and is making an extensive clinical effort to develop new Endoret indications and application protocols, thus improving the quality of treatment in a wide range of clinical situations.
Due to its ability to stimulate tissues, its anti-inflammatory potential and its bacteriostatic effect, Endoret® (PRGF®) has great potential as a treatment for capillary and dermatological conditions.